MOUNTAIN VIEW, Calif., Jan. 5 /PRNewswire/ -- Edison Pharmaceuticals, Inc., a privately held pharmaceutical company, announced today that it has licensed CNTO-530, a clinical-stage compound discovered and developed by Centocor R&D, Inc. for clinical evaluation in rare mitochondrial and other neglected diseases. The terms of the transaction have not been disclosed.
About Edison Pharmaceuticals
Edison Pharmaceuticals is dedicated to developing treatments for children with rare energy-related diseases. The Company's initial focus is on inherited diseases of the mitochondria. Edison is leveraging insights from those studies to pursue other diseases that share common mechanisms.
SOURCE Edison Pharmaceuticals, Inc.